India: Sun, Ranbaxy pharma merger doubted by CCI (Competition Policy International)

The Competition Commission of India has reportedly stepped up scrutiny of the proposed merger between Sun Pharmaceutical Industries and Ranbaxy Laboratories.

The CCI is said to have approached the companies asking they the authority shouldn’t launch an investigation; the regulator also reportedly said the merger would result in significant market strength …read more

Source: Global Competition Law Blogs

Cite this post

OSCOLA

21st Century Competition, 'India: Sun, Ranbaxy pharma merger doubted by CCI (Competition Policy International)' (21st Century Competition, 30 July 2014) <https://www.twentyfirstcenturycompetition.com/2014/07/india-sun-ranbaxy-pharma-merger-doubted-by-cci-competition-policy-international/> accessed 7 April 2026.

Chicago

21st Century Competition. "India: Sun, Ranbaxy pharma merger doubted by CCI (Competition Policy International)." 21st Century Competition, 30 July 2014. https://www.twentyfirstcenturycompetition.com/2014/07/india-sun-ranbaxy-pharma-merger-doubted-by-cci-competition-policy-international/.

BibTeX

@misc{21st-century-competition2014, author = {21st Century Competition}, title = {{India: Sun, Ranbaxy pharma merger doubted by CCI (Competition Policy International)}}, year = {2014}, url = {https://www.twentyfirstcenturycompetition.com/2014/07/india-sun-ranbaxy-pharma-merger-doubted-by-cci-competition-policy-international/}, note = {21st Century Competition} }
Download .bib file